Stock Scorecard
Stock Summary for NewAmsterdam Pharma Company NV (NAMS) - $25.46 as of 12/20/2024 3:50:44 PM EST
Total Score
8 out of 30
Safety Score
29 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NAMS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NAMS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NAMS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NAMS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NAMS (29 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 1 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for NAMS
Financial Details for NAMS
Company Overview |
|
|---|---|
| Ticker | NAMS |
| Company Name | NewAmsterdam Pharma Company NV |
| Country | USA |
| Description | N/A |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 25.46 |
| Price 4 Years Ago | 0.00 |
| Last Day Price Updated | 12/20/2024 3:50:44 PM EST |
| Last Day Volume | 1,026,266 |
| Average Daily Volume | 1,211,707 |
| 52-Week High | 27.29 |
| 52-Week Low | 10.50 |
| Last Price to 52 Week Low | 142.48% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.25 |
| Sector PE | 40.44 |
| 5-Year Average PE | -7.22 |
| Free Cash Flow Ratio | 5.56 |
| Industry Free Cash Flow Ratio | 11.59 |
| Sector Free Cash Flow Ratio | 27.17 |
| Current Ratio Most Recent Quarter | 10.61 |
| Total Cash Per Share | 4.58 |
| Book Value Per Share Most Recent Quarter | 4.11 |
| Price to Book Ratio | 7.21 |
| Industry Price to Book Ratio | 5.00 |
| Sector Price to Book Ratio | 20.63 |
| Price to Sales Ratio Twelve Trailing Months | 81.26 |
| Industry Price to Sales Ratio Twelve Trailing Months | 81.68 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.53 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 92,386,000 |
| Market Capitalization | 2,352,147,560 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -681.73% |
| Reported EPS 12 Trailing Months | -2.21 |
| Reported EPS Past Year | -1.65 |
| Reported EPS Prior Year | -2.55 |
| Net Income Twelve Trailing Months | -198,916,000 |
| Net Income Past Year | -176,937,000 |
| Net Income Prior Year | -22,634,000 |
| Quarterly Revenue Growth YOY | 890.00% |
| 5-Year Revenue Growth | -79.34% |
| Operating Margin Twelve Trailing Months | -0.86 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 422,729,000 |
| Total Cash Past Year | 340,450,000 |
| Total Cash Prior Year | 438,522,000 |
| Net Cash Position Most Recent Quarter | 422,729,000 |
| Net Cash Position Past Year | 340,450,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 288,393,000 |
| Total Stockholder Equity Prior Year | 430,066,000 |
| Total Stockholder Equity Most Recent Quarter | 378,862,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -154,829,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.68 |
| Free Cash Flow Past Year | -141,242,000 |
| Free Cash Flow Prior Year | 10,444,000 |
Options |
|
| Put/Call Ratio | 2.22 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.25 |
| MACD Signal | 0.84 |
| 20-Day Bollinger Lower Band | 12.73 |
| 20-Day Bollinger Middle Band | 19.04 |
| 20-Day Bollinger Upper Band | 25.35 |
| Beta | 0.00 |
| RSI | 60.59 |
| 50-Day SMA | 19.64 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/21/2024 7:05:32 AM EST |